Results 31 to 40 of about 12,993 (261)
Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening
Hepatology Communications, EarlyView., 2022 Abstract Health care initiatives, such as hepatitis C virus (HCV) screening, have been greatly overshadowed by the corona virus disease 2019 (COVID‐19) pandemic. However, COVID‐19 vaccination programs also provide an opportunity to engage with a high volume of people in a health care setting.
Aaron Vanderhoff +17 more
wiley +1 more source
Declining sustained virological response in hepatitis C.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2007 To determine the response of treatment with standard interferon and Ribazole in treatment naïve hepatitis C infected patients, with different grades of activity.A quasi-experimental study.This study was carried out at the Department of Medicine, KRL General Hospital, Islamabad, from January 2001 to September 2004.A total of 300 patients were enrolled ...
Uzma, Batool, Saleem, Qureshi
openaire +2 more sources
Gut and Liver, 2021 Background/Aims: Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes.
Young Joo Park +10 more
doaj +1 more source
Cadernos de Saúde Pública, 2018 : The latest Brazilian guideline recommended the reduction of routine CD4+ T cell counts for the monitoring of patients with human immunodeficiency virus type 1 (HIV-1) under combination antiretroviral therapy (cART).
Ingridt Hildegard Vogler +4 more
doaj +1 more source
Hepatitis C Prevalence and Responses to Pegylated Interferon + Ribavirin Treatment Among Prisoners
Viral Hepatitis Journal, 2017 Objective: The aim of our study was to identify the hepatitis C prevalence in prisoners and to share experiences of pegylated interferon (peg-IFN) + ribavirin (RBV) treatment.
Hasan Selçuk ÖZGER +4 more
doaj +1 more source
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C [PDF]
Clinical and Molecular Hepatology, 2019 Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral agent is very safe and highly effective (
Seong Kyun Na, Byung-Cheol Song
doaj +1 more source
Metabolism Open, 2021 Background and aim: The incidence of hepatocellular carcinoma (HCC) decreases significantly in chronic hepatitis C (CHC) patients with sustained virologic response (SVR) after pegylated-interferon plus ribavirin (PR) or direct-acting antiviral (DAAs ...
Dong Ji +11 more
doaj +1 more source
Meta‐analysis: insulin resistance and sustained virological response in hepatitis C [PDF]
Alimentary Pharmacology & Therapeutics, 2011 Aliment Pharmacol Ther 2011; 34: 297–305SummaryBackground A higher baseline homeostasis model assessment of insulin resistance (HOMA‐IR) score has sometimes predicted a poorer sustained virological response (SVR) rate to peginterferon/ribavirin therapy in treatment‐naïve chronic hepatitis C patients.Aim To perform a meta‐analysis to evaluate the ...
Eslam, Mohammed +6 more
openaire +2 more sources
The Korean Journal of Gastroenterology, 2016 Background : /Aims: The optimal timing for discontinuing oral antiviral therapy in patients with HBeAg-positive chronic hepatitis B (CHB) is unclear. The aim of our study was to investigate sustained remission after stopping antiviral therapy in patients
Baek Gyu Jun +9 more
doaj +1 more source
Libyan Journal of Medicine, 2021 Background/Aims. Despite the high efficacy and safety of direct-acting antivirals against hepatitis C virus shown in clinical trials, treatment failures continue to occur.
María E. Cárdaba-García +2 more
doaj +1 more source